Cargando…
Optimal extent of lymphadenectomy for radical surgery of pancreatic head adenocarcinoma: 2-year survival rate results of single-center, prospective, randomized controlled study
BACKGROUND: Radical pancreaticoduodenectomy is the only possible cure for pancreatic head adenocarcinoma, and although several RCT studies have suggested the extent of lymph node dissection, this issue remains controversial. This article wanted to evaluate the survival benefit of different lymph nod...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415937/ https://www.ncbi.nlm.nih.gov/pubmed/34477122 http://dx.doi.org/10.1097/MD.0000000000026918 |
_version_ | 1783748069187125248 |
---|---|
author | Wang, Ziyao Ke, Nengwen Wang, Xin Wang, Xing Chen, Yonghua Chen, Hongyu Liu, Jinheng He, Du Tian, Bole Li, Ang Hu, Weiming Li, Kezhou Liu, Xubao |
author_facet | Wang, Ziyao Ke, Nengwen Wang, Xin Wang, Xing Chen, Yonghua Chen, Hongyu Liu, Jinheng He, Du Tian, Bole Li, Ang Hu, Weiming Li, Kezhou Liu, Xubao |
author_sort | Wang, Ziyao |
collection | PubMed |
description | BACKGROUND: Radical pancreaticoduodenectomy is the only possible cure for pancreatic head adenocarcinoma, and although several RCT studies have suggested the extent of lymph node dissection, this issue remains controversial. This article wanted to evaluate the survival benefit of different lymph node dissection extent for radical surgical treatment of pancreatic head adenocarcinoma. METHODS: A total of 240 patients were assessed for eligibility in the study, 212 of whom were randomly divided into standard lymphadenectomy group (SG) or extended lymphadenectomy group (EG), there were 97 patients in SG and 95 patients in EG receiving the radical pancreaticoduodenectomy. RESULT: The demography, histopathology and clinical characteristics were similar between the 2 groups. The 2-year overall survival rate in the SG was higher than the EG (39.5% vs 25.3%; P = .034). The 2-year overall survival rate in the SG who received postoperative adjuvant chemotherapy was higher than the EG (60.7% vs 37.1%; P = .021). There was no significant difference in the overall incidence of complications between the 2 groups (P = .502). The overall recurrence rate in the SG and EG (70.7% vs 77.5%; P = .349), and the patterns of recurrence between 2 groups were no significant differences. CONCLUSION: In multimodality therapy system, the efficacy of chemotherapy should be based on the appropriate lymphadenectomy extent, and the standard extent of lymphadenectomy is optimal for resectable pancreatic head adenocarcinoma. The postoperative slowing of peripheral blood lymphocyte recovery might be 1 of the reasons why extended lymphadenectomy did not result in survival benefits. CLINICAL TRIAL REGISTRATION: This trial was registered at ClinicalTrials.gov (NCT02928081) in October 7, 2016. https://clinicaltrials.gov/ |
format | Online Article Text |
id | pubmed-8415937 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-84159372021-09-07 Optimal extent of lymphadenectomy for radical surgery of pancreatic head adenocarcinoma: 2-year survival rate results of single-center, prospective, randomized controlled study Wang, Ziyao Ke, Nengwen Wang, Xin Wang, Xing Chen, Yonghua Chen, Hongyu Liu, Jinheng He, Du Tian, Bole Li, Ang Hu, Weiming Li, Kezhou Liu, Xubao Medicine (Baltimore) 7100 BACKGROUND: Radical pancreaticoduodenectomy is the only possible cure for pancreatic head adenocarcinoma, and although several RCT studies have suggested the extent of lymph node dissection, this issue remains controversial. This article wanted to evaluate the survival benefit of different lymph node dissection extent for radical surgical treatment of pancreatic head adenocarcinoma. METHODS: A total of 240 patients were assessed for eligibility in the study, 212 of whom were randomly divided into standard lymphadenectomy group (SG) or extended lymphadenectomy group (EG), there were 97 patients in SG and 95 patients in EG receiving the radical pancreaticoduodenectomy. RESULT: The demography, histopathology and clinical characteristics were similar between the 2 groups. The 2-year overall survival rate in the SG was higher than the EG (39.5% vs 25.3%; P = .034). The 2-year overall survival rate in the SG who received postoperative adjuvant chemotherapy was higher than the EG (60.7% vs 37.1%; P = .021). There was no significant difference in the overall incidence of complications between the 2 groups (P = .502). The overall recurrence rate in the SG and EG (70.7% vs 77.5%; P = .349), and the patterns of recurrence between 2 groups were no significant differences. CONCLUSION: In multimodality therapy system, the efficacy of chemotherapy should be based on the appropriate lymphadenectomy extent, and the standard extent of lymphadenectomy is optimal for resectable pancreatic head adenocarcinoma. The postoperative slowing of peripheral blood lymphocyte recovery might be 1 of the reasons why extended lymphadenectomy did not result in survival benefits. CLINICAL TRIAL REGISTRATION: This trial was registered at ClinicalTrials.gov (NCT02928081) in October 7, 2016. https://clinicaltrials.gov/ Lippincott Williams & Wilkins 2021-09-03 /pmc/articles/PMC8415937/ /pubmed/34477122 http://dx.doi.org/10.1097/MD.0000000000026918 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | 7100 Wang, Ziyao Ke, Nengwen Wang, Xin Wang, Xing Chen, Yonghua Chen, Hongyu Liu, Jinheng He, Du Tian, Bole Li, Ang Hu, Weiming Li, Kezhou Liu, Xubao Optimal extent of lymphadenectomy for radical surgery of pancreatic head adenocarcinoma: 2-year survival rate results of single-center, prospective, randomized controlled study |
title | Optimal extent of lymphadenectomy for radical surgery of pancreatic head adenocarcinoma: 2-year survival rate results of single-center, prospective, randomized controlled study |
title_full | Optimal extent of lymphadenectomy for radical surgery of pancreatic head adenocarcinoma: 2-year survival rate results of single-center, prospective, randomized controlled study |
title_fullStr | Optimal extent of lymphadenectomy for radical surgery of pancreatic head adenocarcinoma: 2-year survival rate results of single-center, prospective, randomized controlled study |
title_full_unstemmed | Optimal extent of lymphadenectomy for radical surgery of pancreatic head adenocarcinoma: 2-year survival rate results of single-center, prospective, randomized controlled study |
title_short | Optimal extent of lymphadenectomy for radical surgery of pancreatic head adenocarcinoma: 2-year survival rate results of single-center, prospective, randomized controlled study |
title_sort | optimal extent of lymphadenectomy for radical surgery of pancreatic head adenocarcinoma: 2-year survival rate results of single-center, prospective, randomized controlled study |
topic | 7100 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415937/ https://www.ncbi.nlm.nih.gov/pubmed/34477122 http://dx.doi.org/10.1097/MD.0000000000026918 |
work_keys_str_mv | AT wangziyao optimalextentoflymphadenectomyforradicalsurgeryofpancreaticheadadenocarcinoma2yearsurvivalrateresultsofsinglecenterprospectiverandomizedcontrolledstudy AT kenengwen optimalextentoflymphadenectomyforradicalsurgeryofpancreaticheadadenocarcinoma2yearsurvivalrateresultsofsinglecenterprospectiverandomizedcontrolledstudy AT wangxin optimalextentoflymphadenectomyforradicalsurgeryofpancreaticheadadenocarcinoma2yearsurvivalrateresultsofsinglecenterprospectiverandomizedcontrolledstudy AT wangxing optimalextentoflymphadenectomyforradicalsurgeryofpancreaticheadadenocarcinoma2yearsurvivalrateresultsofsinglecenterprospectiverandomizedcontrolledstudy AT chenyonghua optimalextentoflymphadenectomyforradicalsurgeryofpancreaticheadadenocarcinoma2yearsurvivalrateresultsofsinglecenterprospectiverandomizedcontrolledstudy AT chenhongyu optimalextentoflymphadenectomyforradicalsurgeryofpancreaticheadadenocarcinoma2yearsurvivalrateresultsofsinglecenterprospectiverandomizedcontrolledstudy AT liujinheng optimalextentoflymphadenectomyforradicalsurgeryofpancreaticheadadenocarcinoma2yearsurvivalrateresultsofsinglecenterprospectiverandomizedcontrolledstudy AT hedu optimalextentoflymphadenectomyforradicalsurgeryofpancreaticheadadenocarcinoma2yearsurvivalrateresultsofsinglecenterprospectiverandomizedcontrolledstudy AT tianbole optimalextentoflymphadenectomyforradicalsurgeryofpancreaticheadadenocarcinoma2yearsurvivalrateresultsofsinglecenterprospectiverandomizedcontrolledstudy AT liang optimalextentoflymphadenectomyforradicalsurgeryofpancreaticheadadenocarcinoma2yearsurvivalrateresultsofsinglecenterprospectiverandomizedcontrolledstudy AT huweiming optimalextentoflymphadenectomyforradicalsurgeryofpancreaticheadadenocarcinoma2yearsurvivalrateresultsofsinglecenterprospectiverandomizedcontrolledstudy AT likezhou optimalextentoflymphadenectomyforradicalsurgeryofpancreaticheadadenocarcinoma2yearsurvivalrateresultsofsinglecenterprospectiverandomizedcontrolledstudy AT liuxubao optimalextentoflymphadenectomyforradicalsurgeryofpancreaticheadadenocarcinoma2yearsurvivalrateresultsofsinglecenterprospectiverandomizedcontrolledstudy |